

**PCT**

WORLD INTELLECTUAL PROPERTY  
ORGANIZATION  
International Bureau

INTERNATIONAL APPLICATION PUBLISHED UNDER



(51) International Patent Classification<sup>6</sup> :

A01N 33/00

A1

(11) I

WO 9608966A1

(43) International Publication Date: 28 March 1996 (28.03.96)

(21) International Application Number: PCT/US95/12503

(22) International Filing Date: 21 September 1995 (21.09.95)

(30) Priority Data:  
311,545 23 September 1994 (23.09.94) US

(71) Applicant: NEW YORK SOCIETY FOR THE RUPTURED  
AND CRIPPLED MAINTAINING THE HOSPITAL FOR  
SPECIAL SURGERY [US/US]; 535 East 70th Street, New  
York, NY 10021 (US).

(72) Inventor: MURRELL, George, Anthony, Calvert; 704/81  
Grafton Street, Bondi Junction, NSW 2022 (AU).

(74) Agents: LUDWIG, S., Peter et al.; Darby & Darby P.C., 805  
Third Avenue, New York, NY 10022 (US).

(81) Designated States: CA, JP, European patent (AT, BE, CH, DE,  
DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE).

**Published**

*With international search report.*

*Before the expiration of the time limit for amending the  
claims and to be republished in the event of the receipt of  
amendments.*

(54) Title: REGULATION OF WOUND HEALING BY NITRIC OXIDE

**(57) Abstract**

A method for enhancement of wound healing by exposure to increased levels of nitric oxide is disclosed. Also disclosed is a method for inhibition of wound healing by decreasing the level of nitric oxide in a wound.

**FOR THE PURPOSES OF INFORMATION ONLY**

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AT	Austria	GB	United Kingdom	MR	Mauritania
AU	Australia	GE	Georgia	MW	Malawi
BB	Barbados	GN	Guinea	NE	Niger
BE	Belgium	GR	Greece	NL	Netherlands
BF	Burkina Faso	HU	Hungary	NO	Norway
BG	Bulgaria	IE	Ireland	NZ	New Zealand
BJ	Benin	IT	Italy	PL	Poland
BR	Brazil	JP	Japan	PT	Portugal
BY	Belarus	KE	Kenya	RO	Romania
CA	Canada	KG	Kyrgyzstan	RU	Russian Federation
CF	Central African Republic	KP	Democratic People's Republic of Korea	SD	Sudan
CG	Congo	KR	Republic of Korea	SE	Sweden
CH	Switzerland	KZ	Kazakhstan	SI	Slovenia
CI	Côte d'Ivoire	LI	Liechtenstein	SK	Slovakia
CM	Cameroon	LK	Sri Lanka	SN	Senegal
CN	China	LU	Luxembourg	TD	Chad
CS	Czechoslovakia	LV	Latvia	TG	Togo
CZ	Czech Republic	MC	Monaco	TJ	Tajikistan
DE	Germany	MD	Republic of Moldova	TT	Trinidad and Tobago
DK	Denmark	MG	Madagascar	UA	Ukraine
ES	Spain	ML	Mali	US	United States of America
FI	Finland	MN	Mongolia	UZ	Uzbekistan
FR	France			VN	Viet Nam
GA	Gabon				

## REGULATION OF WOUND HEALING BY NITRIC OXIDE

### Field of the Invention

This invention pertains to methods for regulating the  
5 healing of damaged tissue by adjusting the concentration of  
nitric oxide in the vicinity of the damaged tissue.

### Background of the Invention

Nitric oxide (NO•) is synthesized from the amino acid  
10 L-arginine by a family of enzymes termed nitric oxide  
synthases. Its small size and its unpaired electron  
(denoted•), make it a highly reactive and locally diffusible  
free radical. Since the discovery in 1987 that endothelium  
derived relaxing factor (EDRF) is, in fact, NO•, (Palmer,  
15 R.M.J. et al., 1988, *Nature* **333**:664-6; Palmer, R.M.J. et al.,  
1987, *Nature*, **327**:524-527) it has become evident that NO• is  
a widely distributed and multi-functional intra- and  
intercellular messenger. There is strong evidence that NO•  
synthesized by vascular endothelium is responsible for the  
20 regulation of blood pressure and the control of platelet  
aggregation (Mollace, V. et al., 1990, *Biochem. Biophys. Res.*  
*Comm.*, **172**:564-9; Rand, M.J. et al., 1992, *Clin. Exp. Pharmacol.*  
*Physiol.*, **19**:147-69; Szabo, C. et al., 1993, *Circulation Res.*,  
**73**:73), and may be involved in vascular injury caused by tissue  
25 deposition of immune complexes (Mulligan et al., *Proc. Natl.*  
*Acad. Sci. USA*, **88**:6338, 1991). In the central nervous system,  
nitric oxide is thought to be a neurotransmitter involved in  
memory and motor function (Bult, H. et al., 1990, *Nature*,  
**345**:346-347; Dawson, T.M. et al., 1991, *Proc. Natl. Acad. Sci.*  
30 *USA*, **88**:7797-7801; Giovannelli, J. et al., 1991, *Proc. Natl.*  
*Acad. Sci. USA*, **88**:7091-7095; Moroz, L.L. et al., 1993,  
*Neuroreport*, **4**:643-6; Knowles, R.G. et al., 1989, *Proc. Natl.*  
*Acad. Sci. USA*, **86**:5159-5162; Snyder, S.H., 1993, *Nature*,  
**364**:577-632). In the peripheral nervous system, a widespread  
35 network of nonadrenergic, noncholinergic nerves use nitric

oxide to modulate gastrointestinal, bladder and corpus cavernosum relaxation and erection. (Moncada, S. et al., 1993, *New Engl. J. Med.*, 329 (27):2002-12; Ward, S.M. et al., 1992, *Am. J. Physiol*, 263:G277-84).

5 NO• is produced in large amounts by an inducible isoform of nitric oxide synthase in macrophages, neutrophils, lymphocytes and peripheral-blood monocytes during immunological reactions and septic shock. (Hevel, J.M. et al., 1991, *J. Biol. Chem.*, 266:22789-22791; Hibbs, J.B. et al, 1988, *Biochem.*  
10 *Biophys. Res. Comm.*, 157:87-94; Nathan, C.F. et al., 1991, *Curr. Opin. Immunol.*, 3:65-70; Salvemini, D. et al., 1990, *Biochem. Biophys. Res. Comm.*, 169:596-601; Szabo, C. et al., 1993, *Circulation Res.*, 73:73). NO• is also produced in keratinocytes in response to inflammatory mediators (Reck et  
15 al., *J. Biol. Chem.*, 267:21277, 1992.) There is also an inducible form of nitric oxide synthase in cartilage. (Murrell, G.A.C. et al., 1994, *International Business Communications 3rd Symposium on Nitric Oxide* : Palmer, R.M. et al., 1993, *Biochem. Biophys. Res. Comm.*, 193:398-405; Stadler,  
20 J. et al., 1991, *J. Immunol.*, 147:3915-20) Constitutive, Ca<sup>++</sup> dependent isoforms of the enzyme found in the brain and blood vessels release NO• at low, relatively stable concentrations.

The present invention relates to a previously uncharacterized role for NO in wound healing. Wound healing  
25 involves the recruitment of inflammatory cells, followed by fibroblasts, to the site of the wound, where collagen and other connective tissue elements are deposited. The collagen fibers then gradually realign to resemble the original connective tissue (e.g. tendon, ligament, skin.) The ability to regulate  
30 this process locally and specifically would be of considerable therapeutic importance e.g. after surgery or trauma. Furthermore, in certain pathological situations, such as arthrofibrosis, Dupuytren's contracture, peritoneal adhesions, frozen shoulder, scleroderma, and keloid formation, over-  
35 expression, and sometimes normal expression, of the repair mechanisms has negative consequences, and it would be desirable to selectively suppress this response.

Conversely, there are many situations in which the healing response in wound healing is delayed or inhibited e.g. in patients with systemic diseases such as liver failure, renal impairment, diabetes, peripheral vascular disease, or in  
5 patients taking drugs that inhibit healing e.g. corticosteroids or immunosuppressive agents. In these cases, additional exogenous NO<sup>•</sup> may enhance the healing response.

Therefore, there is a need in the art for methods and compositions to influence wound healing in a temporally and  
10 spatially regulatable manner.

#### Summary of the Invention

It has now unexpectedly been found that NO<sup>•</sup> acts as an early initiator of wound healing in mammals. The present  
15 invention encompasses a method for promoting the healing of a damaged tendon or other soft tissue in a patient in need of such treatment, by exposing the tissue or tendon to an increased concentration of NO<sup>•</sup>. This increased concentration or level of NO<sup>•</sup> may be achieved by contacting the damaged soft  
20 tissue or tendon with an agent that increases the local concentration of NO<sup>•</sup> i.e. the concentration of NO<sup>•</sup> within, or in the immediate vicinity of, the damaged tendon. The agent may be a compound that increases the activity of NO synthase (NOS) within the tendon, or a compound that provides NO<sup>•</sup> as a  
25 breakdown product.

In another aspect, the invention encompasses a method for inhibiting unwanted wound healing in a patient in need of such treatment, as in e.g. arthrofibrosis, Dupuytren's contracture, peritoneal adhesions, frozen shoulder,  
30 scleroderma, or keloid formation, by contacting the affected tissue with an agent that inhibits the activity of nitric oxide synthase in the tissue.

In another aspect, the invention provides pharmaceutical compositions for promoting the healing of a  
35 damaged tissue, comprising an agent that increases the concentration or level of nitric oxide in the vicinity of the damaged tissue. The invention also provides pharmaceutical compositions for inhibiting unwanted wound healing in or near

a damaged tissue, comprising an agent that reduces the concentration or level of nitric oxide in the vicinity of the damaged tissue.

In still another aspect, the invention provides a method for identifying agents that stimulate the production of nitric oxide in damaged tendons, which comprises the steps of:

- (i) administering a test compound to a mammal;
- (ii) damaging the Achilles tendon in the mammal;
- (iii) allowing the damaged tendon to heal for a predetermined time;
- (iv) measuring nitric oxide synthase activity in the tendon; and

(v) comparing the nitric oxide synthase activity with the nitric oxide synthase activity in an untreated, damaged tendon to determine that the compound causes a significant increase in nitric oxide synthase activity over that observed in a control tendon.

In still another aspect, the invention provides a method for identifying agents that inhibit unwanted wound healing, which comprises the steps of:

- (i) administering a test compound to a mammal;
- (ii) damaging the Achilles tendon in the mammal;
- (iii) allowing the damaged tendon to heal for a predetermined time;
- (iv) measuring the activity of nitric oxide synthase in the tendon; and

(v) comparing the nitric oxide synthase activity with the nitric oxide synthase activity in an untreated damaged tendon to determine that the compound causes a significant decrease in nitric oxide synthase activity over that observed in a control tendon.

#### Brief Description of the Drawings

Figure 1 shows the structures of several NONOates i.e. agents that release NO<sup>•</sup>.

Figure 2 shows the time course of total and Ca-independent nitric oxide synthase activity in surgically divided rat Achilles tendons. Mean  $\pm$  SEM of two independent

determinations, each of them performed in quadruplicates using pooled tendon samples from 4+4 rats in each experimental group. \*\* =  $p < 0.01$  when compared with the uninjured side, + + =  $p < 0.01$  when compared with the other time points; unpaired two-tailed Student's t tests.

Figure 3 shows the time course of a cross-sectional area of uninjured and surgically divided Achilles tendons in rats fed the nitric oxide synthase inhibitor Nw-nitro-L-arginine methyl ester (L-NAME) or its inactive enantiomer Nw-nitro-D-arginine methyl ester (D-NAME). Mean  $\pm$  SEM.  $n = 11, 9, 4, 4, 8, 8$  for D-NAME, L-NAME at day 7; 15; 22.  $< 0.001$  when compared with the uninjured side; paired two-tailed Student's t tests. + =  $p < 0.05$ , + + =  $p < 0.01$ , + + + =  $p < 0.001$  when compared with the control (D-NAME) group; unpaired two-tailed Student's t tests.

Figure 4 shows the ultimate failure load of Achilles tendon constructs of rats fed the nitric oxide synthase inhibitor Nw-nitro-L-arginine methyl ester (L-NAME) or its inactive enantiomer Nw-nitro-D-arginine methyl ester (D-NAME) at day 7. R = surgically divided, L = uninjured Achilles tendon. Mean  $\pm$  SEM,  $n = 11$  (D-NAME),  $n = 9$  (L-NAME). \*\*\* =  $p < 0.001$  when compared with the uninjured side; paired two-tailed Student's t tests. ++ =  $p < 0.01$  when compared with the control (D-NAME) group; unpaired two-tailed Student's t tests.

Figure 5 shows the weight of rats fed the nitric oxide synthase inhibitor Nw-nitro-L-arginine methyl ester (L-NAME) or its inactive enantiomer Nw-nitro-D-arginine methyl ester (D-NAME) or L-arginine (L-arg). Mean SEM,  $n = 8$  for each group. + + + =  $p < 0.001$  when compared with the control (D-NAME) group; unpaired two-tailed Student's t tests.

Figure 6 shows the effects of nitric oxide synthase inhibition on muscle dry weight in rats fed the nitric oxide synthase inhibitor Nw-nitro-L-arginine methyl ester (L-NAME) or its inactive enantiomer Nw-nitro-D-arginine methyl ester (D-NAME) or L-arginine (L-arg). Mean  $\pm$  SEM,  $n = 8$  for each group. + + =  $p < 0.01$  when compared with the control (D-NAME) group; unpaired two-tailed Student's t tests.

Figures 7a and 7b show the time course of the effects of nitric oxide synthase inhibition on walking speed down the first half (Figure 7a) and second half (Figure 7b) of a confined walkway. Rats were fed the nitric oxide synthase inhibitor Nw-nitro-L-arginine methyl ester (L-NAME) or its inactive enantiomer Nw-nitro-D-arginine methyl ester (D-NAME) or L-arginine (L-arg). Mean  $\pm$  SEM,  $n = 8$  for each group.  $+ = p < 0.05$ ,  $+++ = p < 0.001$  when compared with the control (D-NAME) group; unpaired two-tailed Student's  $t$  tests.

Figure 8a and 8b show a time course of weight (Figure 8a) and walking speed (Figure 8b) of rats fed the nitric oxide synthase inhibitor Nw-nitro-L-arginine methyl ester (L-NAME) or its inactive enantiomer Nw-nitro-D-arginine methyl ester (D-NAME) or L-NAME + L-citrulline (L-CIT). Mean  $\pm$  SEM,  $n = 6, 5, 5$  for each group.  $+ = p < 0.05$ ,  $+++ = p < 0.001$  when compared with the control (D-NAME) group; unpaired two-tailed Student's  $t$  tests.

Figure 9a and 9b show the cross-sectional area (a) and ultimate failure load (b) of Achilles tendon constructs 15 days after surgical division (R) and in the uninjured (L) Achilles tendon constructs of rats fed the nitric oxide synthase inhibitor Nw-nitro-L-arginine methyl ester (L-NAME) or its inactive enantiomer Nw-nitro-D-arginine methyl ester (D-NAME) or L-NAME + L-citrulline (L-CIT). Mean  $\pm$  SEM,  $n = 6, 5, 5$  for each group.  $*** = p < 0.001$  when compared with the uninjured side; paired two-tailed Student's  $t$  tests.

#### Detailed Description of the Invention

All patent applications, patents, and literature references cited in this specification are hereby incorporated by reference in their entirety. In case of inconsistencies, the present description, including definitions, will control.

The present invention is directed to enhancing or retarding the natural biological healing process of damaged tendons, ligaments, bones, skin, cornea, and other tissues by regulating the levels of nitric oxide ( $\text{NO}^\bullet$ ) in a spatially and temporally defined manner.



It has been found that local increases in NO• concentrations initiate and enhance wound healing. As shown in Example 1 below, an experimentally induced lesion in the Achilles tendon of a rat causes a transient increase in the activity of nitric oxide synthase (NOS) in the tendon. Furthermore, inhibition of NOS using Nw-nitro-L-arginine methyl ester (L-NAME) depresses the healing process. On this basis, it is contemplated that agents that induce NOS activity and thus increase the local NO• concentration, as well as agents that provide a direct source of NO• (NONOates), will be useful in promoting wound healing. Alternatively, in pathological conditions where repair mechanisms are deleterious, agents that inhibit NOS or, alternatively, agents that scavenge NO•, should be useful in selectively suppressing these processes.

In order to be effective in enhancing wound healing, the concentration or level of NO• to which the wounded tissue is exposed should be increased by at least about 150% and up to about 10,000% (i.e. 100-fold). Preferably, the amount of NO• to which the wounded tissue is exposed as a result of the treatment is between about 150% and about 1000% higher as compared with the amount of NO• to which the wounded tissue is exposed in the absence of such treatment. The most preferred range is between about 400% and about 1000% the amount of NO• to which the wounded tissue is normally exposed.

Conversely, in order to be effective in inhibiting wound healing, the concentration or level of NO• to which the tissue is exposed should be decreased by at least 50% and up to 100% of the amount of NO• to which the tissue is exposed in the absence of treatment. Preferably, NO• is decreased by at least 75%, and most preferably, by at least 90%.

The present invention encompasses the therapeutic use of agents that stimulate or inhibit NO• production in clinical practice. The compounds that may be employed to enhance NO• in the vicinity of damaged tissue include without limitation sodium nitroprusside; N-(Ethoxycarbonyl)-3-(4-morpholinyl)sydnone imine (Molsidomine); 3-morpholinosydnonimine (SIN-1); 1,2,3,4-Oxatriazolium, 5-amino-3-(3,4-di-chlorophneyl)-chloride (GEA 3162); 1,2,3,4-

Oxatriazolium, 5-amino-3-(3-chloro-2-methyl-phenyl)chloride (GEA 5024); 1,2,3,4-Oxatriazolium, 3-(3-chloro-2-methylphenyl)-5-[[[cyanomethylamino]carbonyl]amino]-hydroxide inner salt (GEA 5583); S-nitroso-N-acetyl-D,L-penicillamine (SNAP); 1-[(4',5'-  
5 Bis(carboxymethoxy)-2'-nitrophenyl)methoxy]-2-oxo-3,3-diethyl-1-triazene dipotassium salt (CNO-4); and [1-(4',5'-Bis(carboxymethoxy)-2'-nitrophenyl)methoxy]-2-oxo-3,3-diethyl-1-triazine diacetoxymethyl ester (CNO-5), all of which are available from Alexis Corp. (San Diego, CA). Additional  
10 compounds include nitroglycerin, diethylamine-NO (DEA/NO), IPA/NO, spermine-NO (SPER/NO), sulfite-NO (SULFI/NO), OXI/NO, and DETA/NO, the synthesis of which is described in Drago, R.S., in *Free Radicals in Organic Chemistry* (Advances in Chemistry Series), Number 36, pages 143-149, 1962; and in  
15 Maragos et al., *J. Med.Chem.* 34:3242, 1991. Briefly, these compounds are prepared by reaction of nitric oxide with a nucleophile. The preferred NO•-generating compound is DETA/NO, which has a half-life of about 1 day and is thus particularly suited for sustained-released formulations  
20 described below (Hrabie et al., *J.Org.Chem.* 58:1472, 1993). The structures of some of these compounds, which are collectively known as NONOates, are illustrated in Figure 1.

The compounds that may be employed to reduce the concentration of NO• in the vicinity of damaged tissue include  
25 without limitation L-NAME, monomethyl arginine (NMMA), aminoguanidine or its derivatives, and N-w-nitro-L-arginine (L-NMA). The preferred compound to use to reduce NO• in the vicinity of damaged tissue is NMMA (Alexis Corp., San Diego, CA). In addition, compounds such as CPTIO (2-(4-carboxyphenyl)-  
30 4,4,5,5,-tetramethylimidazoline-1-oxyl-3-oxide, Alexis Corp.) that scavenge NO• may also be used.

In addition to the compounds identified above, it is possible to use other NO•-generating or NO•-inhibiting compounds, provided they are biologically acceptable i.e. non-  
35 toxic under the conditions of treatment employed. These compounds may be identified using the methods described below.

The types of tissue that may be treated using the methods of the present invention include without limitation

human and other mammalian muscle, tendons, ligaments, skin, mucosae, bone, cartilage, and cornea. The tissue may be damaged by surgical incisions, trauma, or other endogenous pathological processes, and healing may be inadequate due to  
5 systemic diseases such as liver failure, renal impairment, diabetes, peripheral vascular disease, or the administration of drugs that inhibit healing e.g. corticosteroids or immunosuppressive agents. Conversely, excessive healing may occur in arthrofibrosis (scar formation following surgery or  
10 injury to joints), heterotopic ossification (inappropriate bone formation), Ledderhosen's syndrome (Dupuytren's contracture of the feet), peritoneal adhesions, frozen shoulder, scleroderma, keloid formation, and excess scar formation in the skin, around surgically repaired tendons, and around surgical implants.

15 The active NOS stimulators, NONOates or NOS inhibitor compounds can be administered in conjunction with any pharmaceutically acceptable carrier known in the art, e.g. in sterile isotonic saline; creams or ointments such as those containing waxes, fatty acids, and propylene glycol; sprays;  
20 subcutaneous pumps; or slow-release formulations such as those containing polylactic acid-polyglycolic acid (PLAGA). It is contemplated that the concentrations that are locally effective in the rat system will approximate those that are effective in humans and other animals. Thus, the active compounds are  
25 formulated at concentrations ranging from about 0.1 mg/ml to about 5 mg/ml, preferably about 0.4 mg/ml. The pharmaceutical formulations of the present invention need not in themselves contain the entire amount of the agent that is effective in promoting or inhibiting healing, as such effective amounts can  
30 be reached by administration of a single application or dose, or a plurality of applications or doses of such pharmaceutical formulations.

In addition to the active compound, the formulation may comprise analgesics (e.g. lidocaine), antioxidants (e.g.  
35 superoxide dismutase, vitamin C, vitamin E) inhibitors of xanthine oxidase (e.g. allopurinol), corticosteroids, or combinations thereof.

NOS stimulators, NONOates, NOS inhibitors, or NO• scavengers may be administered topically or internally at the site of a wound, or applied during surgery. The only limitation on the route of administration is that the NO•-generating or NO•-inhibiting compounds must be available to increase or decrease the concentration of NO• in the vicinity of the damaged tissue for a sufficient period of time to enhance or inhibit wound healing, respectively. The NO•-generating or -inhibiting compounds may also be injected directly into damaged tissue, including intraarticular injection, or may be included in irrigation, lavage, or fluid used to distend and irrigate joints during arthroscopic surgery. In one embodiment, an NO•-generating compound is administered within 0-96 hours after trauma or surgery. In another embodiment, an NO•-generating agent is administered for a chronic condition e.g. ulceration, tennis elbow, jumper's knee, or a wound that has not healed.

Because NO• affects many physiological processes, for optimal use in practicing the present invention an agent should act locally i.e. within or in the immediate vicinity of a damaged tissue. In some cases, the anatomy of the affected tissue (e.g. a joint, or an area of skin) naturally restricts the activity of the agent to the damaged tissue or its immediate environment. In other cases, this restriction is achieved by employing a formulation (such as a cream, ointment, or slow-release polymer) that limits the diffusion of the agent, or by employing an agent with a relatively brief duration of activity.

In one embodiment, an NO•-inducing agent is formulated in a spray that is applied to the site of a wound or a surgical lesion.

In another embodiment, an NO-inducing agent is formulated as a gel, cream, or surgically implanted polymer, and used to treat ulcers, slow healing wounds, muscle injuries, tendon and ligament injuries, and fractures.

In another embodiment, an NO•-inhibiting agent is formulated in sterile saline and administered by injection to a local site of excessive healing.

MODEL SYSTEMS:

To identify different agents for use in the methods of the present invention, both a cell culture model and animal model may be employed.

5           **Cell culture model:** In cultured bovine chondrocytes, a  $\text{Ca}^{++}$ -independent isoform of NOS can be induced by exposing the cells to *E. coli* lipopolysaccharide (endotoxin) for periods ranging from several hours to several days (see Example 2 below). Any cultured cell line which produces  $\text{NO}^{\bullet}$  in response  
10 to a stimulus can be used. Cell homogenates are prepared at the appropriate times after exposure to test compounds. The level of NOS activity in the homogenates is assessed by measuring the conversion of  $^3\text{H}$ -L-arginine to  $^3\text{H}$ -L-citrulline (see Example 1). The level of NOS protein is measured  
15 immunochemically. For example, commercially available antibodies to NOS can be used in a radioimmunoassay or ELISA, using methods that are standard in the art. In this manner, both the absolute amount and the specific activity of NOS are determined. Furthermore, the production of  $\text{NO}^{\bullet}$  by cultured  
20 cells can be assessed by measuring the concentration of  $\text{NO}_2^-$ , a stable end-product of  $\text{NO}^{\bullet}$ , utilizing a spectrophotometric method based on the Greiss reaction (Green et al., *Anal. Biochem.* 126:131, 1982).

**Rat model system:** The rat achilles tendon model is  
25 used to test model compounds for biological activity i.e. the ability to promote or inhibit wound healing in vivo. As described in Example 1 below, one Achilles tendon in each rat is transected surgically, and allowed to heal for periods ranging from 6 hours to 14 days. At each time point, the  
30 degree of healing is first assessed by measuring walking speed. The animals are then sacrificed and the tendons are excised and subjected to biomechanical testing and morphological and immunochemical analysis. NOS activity is measured in the excised tendons as above. Finally, body and muscle weight are  
35 monitored, and systemic and local toxicity are assessed by macroscopic and microscopic post-mortem examination. It will be understood by a skilled practitioner that any small mammal

suitable for testing may be used, including rats, mice, rabbits, guinea pigs, and the like.

According to the present invention, agents that induce the production of NO• may be identified by the sequential use of the cell culture and animal model systems. Candidate compounds are first tested for their ability to cause a significant increase in NOS activity in the cell cultures i.e. at least 50% over the level present in the cell culture in the absence of the compound. Positive compounds are then administered to rats for several days prior to surgery, and administration is continued following surgery. Alternatively, the compounds are applied directly to the site during surgery. Test compounds that cause more rapid or more extensive healing, and exhibit little or no toxicity, are candidates for useful pharmacological agents. It will be understood by those skilled in the art that the preferred administration regimen for a given compound or treatment can be easily optimized by repeating the in vivo bioassay using different concentrations of the agent and different times of exposure.

A similar experimental protocol may be used to identify inhibitors of NO• production. In this case, the cell cultures are exposed to a stimulus that induces NOS, in the presence or absence of test compounds. Compounds that inhibit the increase in NO• production by at least 50% are then tested in vivo in the rat model for their ability to inhibit normal wound healing. A preferred inhibitory compound is Nw-nitro-L-arginine methyl ester (L-NAME), a structural analogue of L-arginine and a competitive inhibitor of nitric oxide synthase (see Example 1 below), which in the rat system is administered at a concentration of 1 mg/ml in the drinking water *ad libitum* for four days prior to surgery and throughout the post-operative period.

The following working examples are intended to serve non-limiting illustrations of the present invention.

Example 1: An Animal Model System for  
The Role of NO in Wound Healing

The experiments described below were performed to determine if NOS activity is enhanced during wound healing in a rat model system, and to assess the effects of inhibiting NOS on tendon healing.

A. MATERIALS AND METHODS

Nicotinamide adenine dinucleotide phosphate (NADPH), calmodulin, valine, Nw-nitro-L-arginine methyl ester (L-NAME), Nw-nitro-D-arginine methyl ester (D-NAME), L-arginine, L-citrulline,  $\beta$ -NADPH, nitroblue tetrazolium, Triton X and Dowex 50W anion exchange resin were obtained from Sigma Chemical Co., St Louis, MO. NG-methyl-L-arginine monoacetate (L-NMMA) were obtained from Calbiochem (Nottingham, UK). Bromphenol blue was purchased from BioRad Laboratories (Hercules, CA). L-(2,3,4,5- $^3\text{H}$ ) arginine hydrochloride was obtained from Amersham (Buckinghamshire, UK). Tetrahydrobiopterin was obtained from B. Schircks Laboratories (Basel, Switzerland). Anti-nitric oxide synthase antibodies EC-NOS and mac-NOS were purchased from Transduction Laboratories, Lexington, KY.

EXPERIMENTAL DESIGN

One hundred and twenty three outbred male Sprague-Dawley rats (Harlan Sprague Dawley Inc, Indianapolis, IN), weight 250-300g were utilized for testing for nitric oxide synthase activity, histological and immunohistochemical evaluation, and nitric oxide synthase inhibition experiments. NOS activity was determined at 6 hrs (n = 8), 1 day (n = 8), 7 days (n = 8) and 14 days (n = 8) in both the surgically divided and uninjured Achilles tendon. Immunohistochemistry and histological evaluation of uninjured and surgically divided Achilles tendons was performed at day 1 (n = 2), day 4 (n = 2), day 7 (D-NAME, n = 6; L-NAME, n = 6), and day 14 (n = 2).

In the following NOS inhibition experiments, animals were fed the indicated chemicals at 1 mg/ml in their drinking water *ad libitum* for four days prior to surgical division of the right Achilles tendon and throughout the post-operative



experimental period, with the exception of experiment (c)\*, where the drugs were given from the immediate post-operative period:

(a) 1 week D-NAME (n = 9) vs L-NAME (n = 11);  
5 walking speed and biomechanical analyses at day 7.

(b) 2 weeks water (n = 4) vs L-NAME (n = 4);  
morphological and histological analyses at day 14.

(c) 2 weeks D-NAME (n = 6), L-NAME (n = 4), L-NAME  
+ L-citrulline (n = 5)\*; walking speed assessments at day 8 and  
10 15, biomechanical analyses at day 15.

(d) 3 weeks D-NAME (n = 8), L-NAME (n = 8), L-  
arginine (n = 8), walking speed assessments at days  
1,4,8,11,15,18,22, biomechanical assessment, muscle weight and  
autopsy at day 22.

15 L-NAME (Nw-nitro-L-arginine methyl ester) is a  
structural analogue of L-arginine and is a competitive  
inhibitor of nitric oxide synthase. D-NAME (Nw-nitro-D-  
arcinine methyl ester) is its enantiomer, which fails to inhibit  
nitric oxide synthase (control). L-arginine was used as a  
20 potential positive control, since if Larginine were in relative  
short supply, NO• synthesis from nitric oxide synthase might  
be enhanced by the addition of L-arginine. The combination of  
L-NAME and L-citrulline was used as a control to monitor the  
potential effects of L-citrulline depletion.

25

#### SURGICAL PROCEDURES

The rats were housed in beta-chip-lined plastic  
cages, two animals per cage, with a 12-hour light, 12 hour dark  
cycle in an animal care facility and fed rat chow and water ad  
30 libitum. Anaesthesia was achieved by intraperitoneal injection  
of 80 mg/kg ketamine (Park Davis, Morris Plains, NJ) and 5  
mg/kg xylazine (Miles Inc, Shawnee Mission, KS). All surgical  
procedures were performed under sterile conditions with the aid  
of 2.5x microsurgical loops. The surgical procedure was  
35 similar to that previously outlined. A 3 cm midline incision  
was made over the right Achilles tendon and the Achilles tendon  
and plantaris were isolated from the surrounding fascia. The  
underlying fascia was disrupted by spreading with a pair of



small straight scissors. The tendinous portion of the plantaris was removed and the Achilles tendon was divided cleanly in its mid-substance, 0.5 cm from its calcaneal insertion with a scalpel. The skin was then sutured with two  
5 simple nylon sutures of 5-0 ethilon monofilament nylon on a PC-1 cutting needle (Ethicon Inc, NJ). No operation was performed on the left, uninjured, hind limb. No cast or dressings were applied and the animals were unrestricted during the healing phase. The animals were sacrificed by CO<sub>2</sub> inhalation.

#### 10 WALKING SPEED ASSESSMENT

The animals were tested in a confined walkway with a dark shelter at the end. Each rat was held by its chest at the start of the walkway and then allowed to walk/run to the dark shelter at the end of the walkway. The time taken for the  
15 rat to cover the first half (21.5 cm) and the total length (43 cm) of the walkway was measured by individuals blinded to the treatment groups.

#### BODY AND MUSCLE WEIGHT

20 All animals were weighed prior to surgery, at weekly intervals, and at sacrifice. After sacrifice the right triceps of rats fed D-NAME (n = 8), L-NAME (n = 8) or L-arginine (n = 8) for three weeks was harvested, weighed for wet weight, lyophilized for dry weight and the water content calculated.

25

#### BIOMECHANICAL TESTING

One hundred and fifty two harvested lower limbs were placed in phosphate buffered saline (PBS), frozen and stored at  
30 -70°C for an average of seven days prior to testing. On the day prior to testing the specimens were thawed. All extraneous soft and hard tissues were removed by blunt and sharp dissection from the Achilles tendon, formerly intramuscular tendinous fibers and the hind foot. Area measurements of the  
35 uninjured and sham operated tendons were made with an area micrometer (Mitutoyo, Tokyo, Japan). Length measurements were made with a 0.02 mm calibrated caliper (Draper, Japan). The formerly intramuscular tendinous fibers were then secured

between two strips of white labelling tape with Thick Gel Super Glue® (Super Glue Corporation, NY) such that the distal edge of the tape was 1.0 cm from the calcaneal insertion. The calcaneus was fixed at 45° in an adjustable rubber-gripped clamp (Panavise, Sparks, NV). Throughout the procedure care was taken to ensure that neither the Super Glue® nor the self curing plastic contaminated the tendon proper and the specimens were kept moist by application of PBS. Mechanical testing was carried out using a MTS 810 material test system (MTS Systems Corporation, PN). Each specimen underwent a constant velocity ramp to failure test at 1 cm/sec (~100%/sec). Voltage-time and displacement-time histories for each test were transferred to a 486/33C computer (Gateway 200, North Sioux City, SD) for subsequent data analysis. At the completion of testing, each specimen was inspected for type of failure, i.e. substance tear versus avulsion.

#### MORPHOLOGY AND IMMUNOHISTOCHEMISTRY

Experimental and uninjured Achilles tendons were immediately placed in 5% polyvinyl alcohol for one hour, frozen in liquid nitrogen and stored at -70°C. Coronal cryostat sections of the mid-substance of the Achilles tendons were cut at 5 µm, stained with Hematoxylin and Eosin, and examined by individuals blinded to the treatment group. Direct immunofluorescence staining was performed utilizing antibodies to human macrophage nitric oxide synthase (mac-NOS) and endothelial nitric oxide synthase (EC-NOS), purified from mouse ascites in a dilution of 1:500 in phosphate buffered saline (PBS), and fluorescent labelled goat IgG A and M (Cappel, NY) diluted 1:100 in PBS. The slides were then mounted and examined and photographed under direct immunofluorescence with an Aiophot Immunofluorescence Microscope (Zeiss, Oberkochen, Germany).

#### 35 NITRIC OXIDE SYNTHASE ASSAY

Immediately after sacrifice both the left (un-injured) and the right (previously surgically divided) Achilles tendons were harvested at 6 hrs, 24 hrs, 7 and 14 days after

surgery (n = 8 for each group) and quickly frozen in liquid nitrogen. Samples were homogenized on ice using an Ultra-Turrax T 25 homogenizer (Janke & Kunkel, IKA Labortechnik, Staufen I, Br., Germany) in a homogenization buffer composed of: 50 mM Tris-HCl, 0.1 mM EDTA, 0.1mM EGTA, 12 mM 2-mercaptoethanol and 1 mM phenylmethanesulfonyl fluoride (pH 7.4).

Conversion of  $^3\text{H}$ -L-arginine to  $^3\text{H}$ -L-citrulline was measured in the homogenates as described. Briefly, each cell homogenate (40  $\mu\text{l}$ ) was incubated in the presence of  $^3\text{H}$ -L-arginine (10  $\mu\text{M}$ , 5 kBq/tube), NADPH (1 mM), tetrahydrobiopterin (5  $\mu\text{M}$ ), valine (50 mM), calcium (2 mM) and calmodulin (30 nM) for 30 min at 37°C in HEPES buffer (pH 7.5). The reaction was stopped by dilution with 1 ml of ice cold HEPES buffer (pH 7.5) containing EGTA (2 mM) and EDTA (2 mM). Reaction mixtures were applied to Dowex 50W ( $\text{Na}^+$  form) columns and the eluted  $^3\text{H}$ -L-citrulline activity was measured by scintillation spectroscopy (Beckman, LS3801; Fullerton, CA, USA).

Experiments performed in the absence of calcium and in the presence of EGTA (5 mM) determined the calcium-independent NOS activity. Parallel experiment in the presence of calcium and L-NMMA (3 mM) determined the extent of detection and/or formation of  $^3\text{H}$ -L-citrulline that was independent of specific NOS activity, and this was subtracted from all values. The data represent means of two independent determinations, each of them performed in quadruplicates using pooled tendon samples from 4-4 rats in each experimental group.

#### STATISTICAL ANALYSIS

All values in the text and figures are expressed as mean  $\pm$  standard error of the mean of n observations. Statistical analysis between experimental groups was performed using unpaired two-tailed Student's t tests. Statistical analysis between the right surgically divided and the left uninjured were performed using paired two-tailed Student's t tests. The confidence limit was predetermined at an alpha level of 0.05.

**B. RESULTS****EFFECTS OF SURGERY**

The macroscopic appearance of uninjured tendons was that of glistening, pearly-white, longitudinally arranged structures 1 cm long, and 2.5 - 3.0 mm<sup>2</sup> in cross-section. In contrast, all tendons previously subjected to surgical division were opaque structures 10-17 mm long and 6-10 mm<sup>2</sup> in cross-sectional area. At the microscopic level, uninjured tendons consisted of dense, parallel bundles of homogeneous eosinophilic substance aligned with the long axis of the tendon. Interspersed within this matrix were a few longitudinally arranged spindle and oval shaped fibroblasts with prominent nuclei and sparse cytoplasm.

In the divided Achilles tendons, the area between the cut ends of the tendon initially was filled with a loose connective tissue matrix containing numerous inflammatory cells (neutrophils, basophils, macrophages and lymphocytes) and erythrocytes. Over 15 days this loose connective tissue matrix was replaced by a more homogeneous, denser eosinophilic matrix. Plump fibroblasts with large nuclei were the predominant cell type, and were aligned in the longitudinal axis of the tendon. The junction between the old tendon and the new matrix was characterized by a dense (0.1 mm) band of oval shaped fibroblasts with little organization. With time, the tendon-new matrix interface and the band of disorganized fibroblasts became less distinct. The collagenous tissue also became more organized, with fewer fibroblasts and more matrix.

**NITRIC OXIDE SYNTHASE ACTIVITY**

In uninjured tendon samples, very low Ca<sup>++</sup>-dependent and negligible Ca<sup>++</sup>-independent nitric oxide synthase activity was detected. At 6 hrs and 24 hrs post surgery there was a slight increase in Ca<sup>++</sup>-dependent and Ca<sup>++</sup>-independent nitric oxide synthase. By day 7, there was a five-fold increase in Ca<sup>++</sup>-dependent nitric oxide synthase activity (Fig 2). At the same time point, no Ca<sup>++</sup>-independent NOS activity was found. At day 14, NOS activity had returned to near normal. The majority of NOS activity at day 14 was, however, Ca<sup>++</sup>-

independent. There were no changes in NOS activity at any of these time points in the uninjured contralateral side (not shown).

## 5 IMMUNOHISTOCHEMISTRY

Sections prepared with the secondary antibody alone, or after 24 hours formaldehyde fixation, showed no immunofluorescence. The intimal cells of blood vessels consistently reacted strongly to EC-NOS and less strongly to mac-NOS in both uninjured tendon and healing tendon. Gastrocnemius and soleus muscle reacted strongly and diffusely to EC-NOS and mac-NOS in both uninjured and healing Achilles tendons. The tendon fiber bundles and fibroblasts within the tendon matrix of uninjured tendons showed no immunofluorescence. This contrasted with the tissue that filled the defect in the Achilles tendon. This tissue reacted strongly to both EC-NOS and mac-NOS. The intensity and number of fibroblasts reacting to NOS antibodies was greatest at day 7. The intensity and distribution of immunofluorescence to mac-NOS and EC-NOS in this healing tissue was slightly different. EC-NOS was distributed diffusely throughout all the fibroblasts within the healing tendinous tissue, often with the greatest intensity at the edges of the cells. Fibroblasts reacting to mac-NOS had a more heterogeneous pattern of immunofluorescence, with some fibroblasts staining very brightly and others less so. The uninjured tendon fibers had minimal immunofluorescence to EC-NOS and mac-NOS through the whole healing period.

## 30 NITRIC OXIDE SYNTHASE INHIBITION

### *Tendon Morphology*

Inhibition of nitric oxide synthase by the L-arginine analogue Nw-nitro-L-arginine methyl ester (L-NAME) given orally four days prior to surgery and throughout the experimental period inhibited the cross-sectional area of healing Achilles tendon by 30% at day 7 ( $p < 0.01$ ), 50% at day 15 ( $p < 0.001$ ) and 17% at day 22 ( $p < 0.05$ ) (Fig 3). Within the healing tendons the cut ends of the tendon were separated by 5-8 mm,

a distance that did not change with healing time or with the administration of L-NAME or L-arginine (not shown).

#### *Light Microscopy*

5            Apart from the decrease in cross-sectional area of the healing tendon of rats fed L-NAME, there were no subjective differences in the microscopic appearance of the healing tissue in L-NAME versus D-NAME fed rats.

#### 10           *Biomechanics*

         All load-deflection curves were non-linear and showed a stiffening response (increasing load with increasing deformation). The failure site of all uninjured tendons was at the distal tendon-calcaneus interface. In the previously  
15 divided tendons, failure occurred at both the proximal clamp-tendon interface, the mid-substance and the tendon-calcaneal interface. The majority of failures at the early time points were in the mid-substance. At day 22 many failures in the healing tendon occurred at the clamp-tendon interface and by  
20 avulsion of the tendinous fibers from the proximal fixation. For this reason the failure load data for the healing tendons at day 22 was disregarded. The healing Achilles tendon constructs had a greater toe displacement, maximum displacement, and had a lower ultimate failure load at day 7,  
25 15 and 22 than uninjured tendon constructs. These differences decreased with healing time (not shown).

         Inhibition of nitric oxide synthase activity with L-NAME caused a 24% reduction in failure load on the formerly divided side ( $p < 0.01$ ) on day 7. The uninjured Achilles tendon  
30 constructs were unaffected by L-NAME ingestion (Fig 4). Inhibition of nitric oxide synthase did not affect toe displacement, maximum displacement, stiffness, energy, modulus or maximum stress of the healing tendons of the surgically divided or uninjured Achilles constructs (not shown.)

35

#### *Weight*

         Rats fed the nitric oxide synthase inhibitor L-NAME either failed to gain weight or lost weight over the first 15

days of treatment, and by day 22 the rats were 30% lighter than their initial preoperative weight ( $p < 0.001$ ; Fig. 5). This contrasted to rats fed the same dose of D-NAME or L-arginine, who all increased their weight by 30% over 22 days.

5

#### *Muscle Weight*

Inhibition of nitric oxide synthase resulted in a 30% loss in wet weight and 40% loss in dry muscle weight at day 22 ( $p < 0.01$ ). L-arginine had no effect (Fig 6).

10

#### *Walking Speed*

There were no changes in behavior or walking speed of nitric oxide synthase inhibited rats during the first week of treatment. After day 11, L-NAME fed rats were progressively  
15 quieter, slower (Figures 7a and 7b) and more reluctant to walk down a confined walkway. L-NAME fed rats were especially reluctant to walk down the second part of the walkway into the dark shelter (Figure 7a versus 7b).

20

#### *Other Systemic Effects*

From day 15, L-NAME fed rats became progressively unwell. Four out of the eight rats in this group developed motor palsies of either the upper limbs ( $n = 1$ ) or lower limbs ( $n = 2$ ). All L-NAME fed rats lost coat texture and developed  
25 peri-orbital rubor. 5/8 developed severe dyspnoea. Two died on day 21, and the whole experiment was shorted to 22 days rather than the planned 28 days. At post mortem examination all L-NAME fed rats had scant body fat, empty small intestines, myocardial lesions consistent with infarction and granular  
30 kidneys. The D-NAME and L-arginine fed rats failed to display any of the above changes.

#### *L-citrulline*

One concern was that these systemic effects were  
35 secondary to a L-citrulline deficiency induced by nitric oxide synthase inhibition rather than a lack of NO, activity. For this reason, a group of rats were fed both L-NAME and L-citrulline and compared with a L-NAME group and a D-NAME group.



L-NAME/L-citrulline fed rats lost weight and walking speed at the same rate as rats fed L-NAME alone (Figs 8a and 8b); implicating a NO deficiency rather than a L-citrulline deficiency as the underlying reason for the systemic effects  
5 of L-NAME.

#### *Post-Injury Nitric Oxide Synthase Inhibition*

The role of nitric oxide synthase in initiating the healing response in divided Achilles tendon was assessed by  
10 feeding rats L-NAME from the immediate post-operative period, rather than for four days preoperatively. With this regimen, the L-NAME fed rats displayed the usual systemic changes at day 15 (weight loss and loss of walking speed; Figs 8a and 8b), but failed to show any changes in tendon cross-sectional area (Fig  
15 9a) or failure load (Fig 9b).

#### C. DISCUSSION

NOS activity was induced during rat Achilles tendon healing. The increased activity was predominantly in  
20 fibroblasts within the healing tissue, was maximal at day 7, and returned to baseline activities at day 14. Inhibition of NOS prior to injury inhibited the magnitude of the healing response (tendon cross-sectional area and failure load). Inhibition of NOS after injury did not alter the healing  
25 response. Systemic inhibition of NOS for more than two weeks resulted in weight loss, muscle mass loss, psychological changes, loss in walking speed and eventually paralysis.

These findings have several important implications for the present invention. First, NO plays an important role  
30 in the initiation of wound healing. Second, agents that inhibit NO production can be used to selectively suppress healing processes when such processes are deleterious. Third, the methods and compositions of the present invention must be locally effective to avoid systemic effects of NO stimulation  
35 or inhibition.

This experiment also taught that proliferating fibroblasts within the healing tendon accounted for most of the new NOS immunofluorescence at day 7 post-surgery, and



biochemical assays demonstrated that the new NOS was primarily Ca-dependent. This supports the use of a cell culture system to induce Ca-dependent NOS as described above.

**5      Example 2: Endotoxin-Induced NO<sup>•</sup> Release From Cultured**

# B o v i n e Chondrocytes

Chondrocytes were obtained from slices of bovine hind-foot articular cartilage or bovine articular occipital cartilage by collagenase digestion as follows: the slices were incubated in 0.25% (w/v) collagenase (Sigma Chemical Co., St. Louis, MO), 1% antibiotic-antimycotic solution, 2% (v/v) HEPES with vigorous agitation at 37°C for six hours. The cell suspension was then centrifuged at 30,000 rpm for 10 min and the supernatant discarded. The cells present in the pellet were resuspended in fresh growth medium (medium 199 or Dulbecco's MEM supplemented with 10% fetal bovine serum) and plated in 75 mm culture flasks.

The production of NO• by these cells was assessed by measuring the concentration of NO<sub>2</sub><sup>-</sup>, a stable end-product of NO•, utilizing a spectrophotometric method based on the Greiss reaction (Green et al., *Anal.Biochem.* 126:131, 1982). The absorbance was measured at 550/650 nm with a 340 ATTC microplate photometer (Tecan US Inc., Research Triangle Park, NC).

No constitutive release of  $\text{NO}_2^-$  was detected in these cultures. However, addition of 1  $\mu\text{g/ml}$  E. coli endotoxin, or of the inflammatory mediators  $\text{IL-1}\beta$  and  $\text{TNF-}\alpha$ , resulted in the release of 100 nmol  $\text{NO}_2^-$  /106 cells/24 hours. The induction of  $\text{NO}_2^-$  by endotoxin was dose- and time-dependent, with maximal stimulation at 24 hours.  $\text{NO}_2^-$  production was completely inhibited by L-NAME, confirming nitric oxide synthase as the source for  $\text{NO}_2^-$  (and, by inference,  $\text{NO}^\bullet$ ). The induction of  $\text{NO}_2^-$  in chondrocytes by endotoxin was not inhibited by EGTA, indicating that the nitric oxide synthase in these cells is not  $\text{Ca}^{++}$ -dependent.

Example 3: Therapeutic Administration of  
an NO<sup>•</sup> Inducer

Following are clinical situations in which NO<sup>•</sup> inducers or NONOates may be administered to promote wound  
5 healing.

A. Ruptured Achilles Tendon: Surgical repair of a ruptured Achilles tendon involves making a midline incision over the Achilles tendon, isolating the ends of the ruptured tendon, and  
10 re-apposing the ends of the tendon with a #1 Ethibond suture configured in a Kessler-type fashion. At the time of surgery, a polyethyleneimine cellulose/NO<sup>•</sup> inducer adduct is mixed with a superabsorbent polymer (Waterlock), prepared by mixing 0.5 g Waterlock with 50 ml sterile water, followed by addition of  
15 0.4g of an NO<sup>•</sup> inducer or NONOate. This mixture is carefully applied around the edges of the re-apposed tendon and in any defects between the tendon edges. This polymer is predicted to release NO<sup>•</sup> at a constant rate over a 7-day period.

20 B. Chronic Skin Ulcer: A typical patient will have a chronic ulcer over his/her tibia. An ointment is formulated having the following composition: white petrolatum (70% v/v); emulsifying waxNF (5% v/v); propylene glycol (10% v/v); propylene carbonate (5% v/v); glyceryl monostearate (5% v/v); white wax (5% v/v);  
25 and an NO<sup>•</sup> inducer (0.4 mg/ml of ointment). The ointment is rubbed into the wound for 5 minutes twice a day until the wound has healed.

C. Soft Tissue Injury: For treatment of a hamstring strain  
30 or other traumatic soft tissue injury, the ointment described in Section B above is rubbed into the skin over the painful area for 5 minutes twice a day, until the injury is pain-free.

Example 4: Clinical Treatments  
Using an NOS Inhibitor

Following are clinical situations in which NO• inhibitors may be administered to prevent unwanted wound healing (i.e. fibrosis), and additionally to prevent arthritis.

5 A. Anterior Cruciate Ligament (ACL) Injury: During surgical reconstruction of an injured ACL, the patient's knee is cleansed with disinfectant, draped, and standard arthroscopic portals are established i.e. supero-medial, supero-lateral, infero-medial and infero-lateral. Inflow is established  
10 through one of the portals. The fluid that irrigates the knee joint at this point and throughout the surgery consists of Ringer's solution (NaCl 8.6 g/L; CaCl<sub>2</sub> 330 mg/L; KCl 300 mg/L; 309 mOsm/L) containing a competitive inhibitor of NOS (e.g. L-NAME) at a concentration of 0.1 mg/ml. 10 ml of the same  
15 solution containing a higher concentration of NOS inhibitor (e.g. 1 mg/ml) is injected into the joint following surgery.

B. Frozen shoulder: This syndrome is defined as a loss of range of motion with or without pain and with no attributable  
20 cause. 10 ml of Ringer's solution as above, containing 1 mg/ml of an NOS inhibitor, is injected into the joint.

#### Example 5: Sustained Release Formulations

A sustained-release formulation of a NONOate for  
25 implantation in a wound is formulated as follows: 20 g DETA/NO and 80 g polylactic acid-polyglycolic acid (PLAGA) are dissolved in 100 ml methyl chloride. 0.5 g polyvinyl alcohol is added. The mixture is stirred for 24 hours, until the solvent has evaporated. The resulting microspheres are washed  
30 in distilled water and freeze-dried, after which they are stored under nitrogen at -20°C.

A sustained-release formulation of an NOS inhibitor for prevention of excessive scar formation e.g. around surgical implants is formulated as follows: 20g of an NOS inhibitor  
35 such as L-NAME and 80 g polylactic acid-polyglycolic acid (PLAGA) are dissolved in 100 ml methyl chloride. 0.5 g polyvinyl alcohol is added. The mixture is stirred for 24 hours, until the solvent has evaporated. The resulting

microspheres are washed in distilled water and freeze-dried, after which they are stored under nitrogen at  $-20^{\circ}\text{C}$ .

WHAT IS CLAIMED IS:

1           1.    A method for promoting the healing of a damaged  
2 tissue in a patient in need of such treatment, comprising  
3 exposing said tissue to an increased concentration of nitric  
4 oxide compared to the concentration of nitric oxide in said  
5 tissue in the absence of such exposure.

1           2.    The method of claim 1 wherein said tissue is a  
2 member selected from the group consisting of muscle, tendon,  
3 ligament, skin, mucosae, bone, and cornea.

1           3.    The method of claim 1 wherein said damage  
2 comprises surgical incisions, trauma, or endogenous  
3 pathological processes.

1           4.    The method of claim 1 which comprises  
2 administering effective amounts for promoting the healing of  
3 said tissue of an agent that increases the concentration of  
4 nitric oxide in said tissue.

1           5.    The method of claim 4 which comprises  
2 administering said agent in a manner that places said agent in  
3 contact with said damaged tissue.

1           6.    The method of claim 4 which comprises increasing  
2 the activity of nitric oxide synthase by administration of said  
3 agent.

1           7.    The method of claim 4 which comprises  
2 administering a NONOate.

1           8.    The method of claim 4 which comprises  
2 administering said agent up to 96 hours after the occurrence  
3 of said damage.

1           9.    The method of claim 4 which comprises  
2 administering said agent via the intravenous, intramuscular,  
3 intraarticular, nasal, or topical route.

1           10. The method of claim 4 which comprises increasing  
2 said concentration of nitric oxide to between about 150% and  
3 about 10,000% of the nitric oxide concentration present in the  
4 absence of said agent.

1           11. A method for promoting the healing of damaged  
2 tendons, comprising contacting said tendons with effective  
3 amounts of an agent that increases the local concentration of  
4 nitric oxide.

1           12. A pharmaceutical composition for promoting the  
2 healing of damaged tissue, said composition comprising an agent  
3 that increases the local concentration of nitric oxide in said  
4 tissue and a pharmaceutically acceptable carrier.

1           13. The composition of claim 12 wherein the  
2 concentration of said agent is between about 0.1 mg/ml and  
3 about 0.5 mg/ml.

1           14. A method for inhibiting unwanted healing in or  
2 near a damaged tissue in a patient in need of such treatment,  
3 comprising reducing the concentration of nitric oxide in said  
4 tissue.

1           15. The method of claim 14 wherein said tissue is  
2 a member selected from the group consisting of muscle, tendon,  
3 ligament, skin, mucosae, bone, and cornea.

1           16. The method of claim 14, which comprises  
2 administering an effective amount for inhibiting unwanted  
3 healing of an agent that reduces the concentration of nitric  
4 oxide in said tissue.

1           17. The method of claim 16, which comprises  
2 administering said agent in a manner that places said agent in  
3 contact with said damaged tissue.

1           18. The method of claim 16, which comprises  
2 administering monomethyl arginine.

1           19. The method of claim 16 which comprises  
2 administering said agent via the intravenous, intramuscular,  
3 intraarticular, nasal, or topical route.

1           20. The method of claim 16, which comprises reducing  
2 the concentration of nitric oxide by about 50% to about 100%  
3 below the concentration of nitric oxide that is present in the  
4 absence of said agent.

1           21. A method for inhibiting the healing of a damaged  
2 tendon, which comprises contacting said tendon with an  
3 effective amount for inhibiting healing of said tendon of an  
4 agent that decreases the concentration of nitric oxide within  
5 said tendon.

1           22. A pharmaceutical composition for inhibiting  
2 unwanted wound healing in or near a damaged tissue, said  
3 composition comprising an agent that reduces the concentration  
4 of nitric oxide in said tissue and a pharmaceutically  
5 acceptable carrier.

1           23. The composition of claim 22 wherein the  
2 concentration of said agent is between about 0.1 mg/ml and  
3 about 0.5 mg/ml.

1           24. A method for identifying agents that stimulate  
2 the production of nitric oxide in damaged tendons, which  
3 comprises:

- 4           (i) administering a test compound to rats;  
5           (ii) damaging the Achilles tendon in said rats;  
6           (iii) allowing said damaged tendons to heal for  
7 a predetermined time;  
8           (iv) measuring the activity of nitric oxide synthase  
9 in said tendons; and


1           (v) comparing said nitric oxide synthase activity  
2 with the nitric oxide synthase activity in an untreated damaged  
3 tendon to determine that said compound causes a significant  
4 increase in nitric oxide synthase activity over that observed  
5 in said control tendon.

1           25. A method for identifying agents that inhibit  
2 unwanted fibroblast proliferation in a damaged tissue, which  
3 comprises:


- 4           (i) administering a test compound to rats;  
5           (ii) damaging the Achilles tendon in said rats;  
6           (iii) allowing said damaged tendons to heal for  
7 a predetermined time;  
8           (iv) measuring the activity of nitric oxide synthase  
9 in said tendons; and  
10          (v) comparing said nitric oxide synthase activity  
11 with the nitric oxide synthase activity in an untreated damaged  
12 tendon to determine that said compound causes a significant  
13 decrease in nitric oxide synthase activity over that observed  
14 in said control tendon.




FIG. 1




Sodium nitroprusside




Molsidomine




DEA/NO




IPA/NO




OXI/NO




SULFI/NO



Nitroglycerin




S-Nitroso-N-acetylpenicillamine (SNAP)



SPER/NO


2/10

FIG. 2




3/10

FIG. 3




4/10

FIG. 4




5/10

FIG. 5




6/10

FIG. 6




7/10

FIG. 7A



8/10

FIG. 7B





9/10  
FIG. 8A





FIG. 8B



10/10

FIG. 9A





FIG. 9B



## INTERNATIONAL SEARCH REPORT

International application No.  
PCT/US95/12503

## A. CLASSIFICATION OF SUBJECT MATTER

IPC(6) : A01N 33/00

US CL : 424/600; 514/150, 183

According to International Patent Classification (IPC) or to both national classification and IPC

## B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

U.S. : 424/600; 514/150, 183

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practicable, search terms used)

## C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X --- A	Chemical Abstracts, Volume 120, issued 1993, Bulgrin et al., "Arginine free diet suppresses nitric oxide production in wounds", Abstract Number 7397, J. Nutr. Biochem., Volume 4, Number 10, issued 1993, pages 588-593, see entire abstract.	1-17, 19-23 ----- 18, 24, 25



Further documents are listed in the continuation of Box C.



See patent family annex.

* Special categories of cited documents:	* T later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
* A* document defining the general state of the art which is not considered to be of particular relevance	* X* document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
* E* earlier document published on or after the international filing date	* Y* document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art
* L* document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)	* &* document member of the same patent family
* O* documents referring to an oral disclosure, use, exhibition or other means	
* P* document published prior to the international filing date but later than the priority date claimed	

Date of the actual completion of the international search

10 JANUARY 1996

Date of mailing of the international search report

22 JAN 1996

Name and mailing address of the ISA/US  
Commissioner of Patents and Trademarks  
Box PCT  
Washington, D.C. 20231

Facsimile No. (703) 305-3230

Authorized officer

JEFFREY MULLIS

Telephone No. (703) 308-1235

**THIS PAGE BLANK (USPTO)**